Table 2. Response by dose level.
| WHO response criteria | 40 mg m−2 group (n=16) | 35 mg m−2 group (n=31) | All patients (n=47) |
|---|---|---|---|
| Complete response | 0 | 0 | 0 |
| Partial response | 2 | 7 | 9 |
| No change | 7 | 10 | 17 |
| Progressive disease | 2 | 9 | 11 |
| (and early PD) | |||
| Nonevaluable | 5 | 5 | 10 |
| Primary site of disease | |||
| Colon | 10 | 21 | 31 |
| Rectum | 4 | 5 | 9 |
| Rectosigmoid | 2 | 5 | 7 |
| Overall response (−%) | 12.5 | 22.6 | 19 |
| (confidence interval) | (2.3–34.4) | (11.1–38.3) | (7.0–37.7) |
| Overall response (+%) | 18.2 | 26.9 | 24 |
| (confidence interval) | (3.3–47.0) | (13.4–44.7) | (9.1–46.3) |
(−%)=response rate on all treated patients; (+%)=response rate on all evaluable patients. PD=progressive disease.